Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paclitaxel cationic liposomes in advanced solid tumors
NCT06632574Phase 1Recruiting
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Mar 2014
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of paclitaxel in solid tumor (advanced stage), sponsored by CSPC ZhongQi Pharmaceutical Technology. Primary endpoints: Incidence of Dose-Limiting Toxicity and Incidence and Severity of Adverse Events and Serious Adverse Events up to 3 years. Started Mar 2014; status: recruiting.
02
Drugs
paclitaxel
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06632574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06632574.